Earnings recovery and improved profitability
First written in FY2022-Q2. 8 of 19 entries say "Advanced", first in FY2022-Q3. Latest entry: 2026-08-06.
PHC Holdings moved to the "Worse" side of this theme in 2023, 2 years after the typical company in this theme (2021).
The whole theme swung hardest in 2018: 2 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2026AdvancedAnnual report
「The Group's revenue for the period was ¥364,403 million, up 0.8% year on year. Operating profit was ¥22,688 million, up 0.5% year on year, and adjusted EBITDA, excluding depreciation and amortization and nonrecurring income and expenses, was ¥51,959 million, up 3.7% year on year.」
Full-year revenue, operating profit, and adjusted EBITDA all exceeded the same period of the previous year, improving operating performance and profitability. However, profit before tax and profit for the year attributable to owners of the parent declined due to foreign exchange losses. - FY2026-H1AdvancedAnnual report
「Operating profit was ¥10,378 million, up 12.7% year on year. Adjusted EBITDA was ¥24,260 million, up 4.2% year on year.」
While revenue declined 0.3% year on year, operating profit and adjusted EBITDA increased, improving operating profitability. However, profit before tax for the interim period declined substantially due to foreign exchange losses, and an interim loss attributable to owners of the parent was recorded. - FY2025AdvancedAnnual report
「The Group's revenue for the fiscal year ending March 2025 was ¥361,593 million, up 2.2% year on year. Operating profit was ¥22,580 million, up 1,341.9% year on year.」
Full-year revenue increased, and operating profit rose substantially from ¥1,566 million in the previous period to ¥22,580 million. Profit before tax and profit for the year attributable to owners of the parent also moved from losses to profits, indicating a recovery in performance and profitability from the previous period. - FY2025-H1AdvancedAnnual report
「The Group's revenue for the interim consolidated accounting period, hereinafter the period, was ¥173,863 million, up 4.2% year on year. Operating profit was ¥9,212 million, up 120.3% year on year.」
Revenue increased, and operating profit rose 120.3% year on year. Profit before tax for the interim period and interim profit attributable to owners of the parent also moved from losses in the same period of the previous year to profits, indicating an improvement in performance and profitability from the previous period. - FY2024WorsenedAnnual report
「Revenue was ¥353,900 million, down 0.7% year on year. Operating profit was ¥1,566 million, down 92.2% year on year. Adjusted EBITDA was ¥49,713 million, down 23.4% year on year.」
Full-year revenue declined, while operating profit and adjusted EBITDA declined substantially. The disclosure also notes that Healthcare Solutions moved into an operating loss and that profit in Diabetes Management declined. - FY2024-Q3WorsenedAnnual report
「The Group's revenue for the nine-month period ended the third quarter, hereinafter the period, was ¥256,683 million, down 3.2% year on year. Operating loss was ¥5,128 million, compared with operating profit of ¥21,429 million in the same period of the previous year. Adjusted EBITDA was ¥33,677 million, down 31.7% year on year.」
Revenue declined, operating profit moved from a profit in the same period of the previous year to an operating loss, and adjusted EBITDA also declined 31.7%. - FY2024-Q2WorsenedAnnual report
「Operating profit was ¥4,182 million, down 60.3% year on year. The main factors were lower profit in Diabetes Management due to the impact of lower revenue in the BGM business and the recognition of costs related to structural reform accompanying a review of the organizational structure, and lower profit in Healthcare Solutions due to a decline in the high-margin PCR testing volumes in the LSIM business.」
Revenue declined 2.2% year on year and operating profit declined 60.3%, resulting in a pretax loss for the quarter of ¥3,030 million and a loss for the quarter attributable to owners of the parent of ¥2,457 million. - FY2024-Q1WorsenedAnnual report
「Operating profit was ¥1,712 million, down 16.3% year on year. Adjusted EBITDA was ¥10,024 million, down 19.5% year on year.」
As revenue declined 0.2% year on year, operating profit and adjusted EBITDA fell 16.3% and 19.5%, respectively, and profitability continued to deteriorate. - FY2023-Q3WorsenedAnnual report
「Operating profit was ¥21,429 million, down 10.9% year on year. Adjusted EBITDA was ¥49,320 million, down 12.8% year on year. Profit before tax for the quarter was ¥7,414 million, down 70.2% year on year.」
Although revenue increased 5.0%, operating profit, adjusted EBITDA, and profit before tax for the quarter all fell below the same period of the previous year, and profitability continued to deteriorate. - FY2023-Q2WorsenedAnnual report
「Operating profit was ¥10,540 million, down 22.2% year on year.」
Although revenue increased 2.7% year on year, operating profit declined 22.2%, adjusted EBITDA declined 19.4%, and profit before tax for the quarter declined 83.1%, with performance and profitability continuing to deteriorate. - FY2023-Q1WorsenedAnnual report
「Operating profit was ¥2,046 million, down 63.7% year on year. Adjusted EBITDA was ¥12,451 million, down 26.8% year on year.」
While revenue increased only 0.7% year on year, operating profit and adjusted EBITDA declined substantially, and performance and profitability deteriorated. - FY2022-Q3AdvancedAnnual report
「Revenue for the nine-month period ended the third quarter was ¥252,368 million, up 14.4% year on year. Operating profit was ¥24,063 million, up 31.1% year on year, and adjusted EBITDA was ¥56,580 million, up 25.5% year on year.」
For the nine months ended the third quarter, revenue, operating profit, and adjusted EBITDA exceeded the same period of the previous year, demonstrating numerically the progress in performance recovery and improved profitability. - FY2022-Q2First statedAnnual report
「The Group's revenue for the period was ¥166,051 million, up 20.6% year on year. Operating profit was ¥13,541 million, up 107.3% year on year, reflecting the positive impact of higher revenue, despite increased selling-related expenses and the recognition of ¥2,958 million in costs related to structural reform in the Diabetes Management business. Adjusted EBITDA was ¥36,907 million, up 56.3% year on year.」
The disclosure presents year-on-year improvements in revenue, operating profit, and adjusted EBITDA as a recovery in performance for the quarter.